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Infectious disease point-of-care test (ID-POCT) devices are becoming widely available, and 
in this respect, international quality standards and guidelines are available for consultation 
once ID-POCT has been implemented into medical institutions. However, specific guidelines 
for consultation during the initial pre-implementation decision-making process are currently 
lacking. Further, there exist pre-implementation issues specific to ID-POCT. Here we present 
pre-implementation guidelines for consultation when considering the implementation of 
ID-POCT in medical institutions.
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Point-of-care test (POCT) devices are widely available for use in medical institutions [1] and in 
this respect, international quality standards and guidelines are available regarding their imple-
mentation [2], for example: ISO 15189:2012 – ‘Requirements for Quality and Competence’ [3]; 
ISO22870:2006 ‘Point-of-Care Testing – Requirements for Quality and Competence’ [4]; 
ID-POCT01-A2 ‘Point-of-Care Connectivity’ – Approved Standard-Second Edition [5] and 
‘Diagnosing Infection at the Point of Care’ [6] etc. However, the implementation of dedicated 
infectious disease POCT (ID-POCT) devices into medical institutions tends to lag behind that of 
POCT devices used in many other medical disciplines, for example, clinical chemistry. Further, 
though many of the implementation issues for POCT and ID-POCT are similar (see references 
above), there still exist crucial pre-implementation differences between POCT and ID-POCT 
before their implementation into medical institutions [7–9].
One of the hurdles to implementing ID-POCT is a lack of specific ID-POCT guidelines and 
solutions which can be used to guide ID-POCT stakeholders, for example, physicians, labora-
tory managers, ID-POCT manufacturers and retailers, financial personnel etc. in their decision 
making before actual implementation issues are decided. Further, there exist specific ID-POCT 
pre-implementation issues which may not be applicable to other forms of POCT devices.
In this Perspective article, the authors present a simple and ‘holistic’ set of ID-POCT guide-
lines that can be used by ID-POCT stakeholders to guide their pre-implementation ID-POCT 
decision-making processes within their own medical institutions. In this respect, ‘holistic’ means 
taking into account the whole range of stakeholders involved in the implementation of ID-POCT 
within medical institutions, including clinicians, diagnosticians, laboratory managers, healthcare 
financiers, manufacturers of ID-POCT and patients (specifically the actual clinical needs of the 
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Figure 1.  Pre-implementation planning for infectious disease point-of-care testing in medical institutions. 
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patient). By including all of these stakehold-
ers in the decision-making process, informed 
and accurate decisions can be made regarding 
the needs and usefulness of ID-POCT within 
individual medical institutions. These guide-
lines are based on the experiences of a recently 
established point-of-care expert group at the 
Erasmus University Medical Center Rotterdam 
(Erasmus MC), a tertiary care university medical 
center based in Rotterdam, the Netherlands, with 
approximately 1,220 hospital beds, and which 
receives approximately 40,000 in-patients and 
500,000 out-patient visits per year. The guide-
lines will be useful to both medical institutions 
and ID-POCT kit manufacturers and encourage 
these organizations (with potentially conflicting 
goals) to better understand and interact with one 
another in order to achieve the successful imple-
mentation of ID-POCT into existing analytical 
workflows within medical institutions. Although 
the intention of this article is to present a ‘uni-
versal’ set of guidelines, it should be noted that 
not all of the suggestions made may be applicable 
to all healthcare providers in all countries and 
Preferred route
Alternative routes
Establish an internal ID-POCT work group:
Create and circulate a ID-POCT questionnaire:
Recruit expert representatives from key departments for which POCT testing is
(or is likely to be) used within your medical institution.
Try to create a ‘holistic’ internal POCT working group which includes clinicians,
diagnosticians, laboratory managers, financiers etc.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Interpret the results and generate advice for circulation to potential POCT users within
the medical institution.
Act on this advice e.g. by creating informational presentations, including on the
advantages and disadvantages of POCT.
Create dissemination pipelines for POCT information internally (also Table 1).
‘Pro-actively’ develop contacts with ID-POCT manufacturers:
The internal ID-POCT working group should be the first line of contact between ID-POCT
manufacturers and individual medical institutions (also Tables 3 & 4).
ID-POCT manufacturers possess useful evaluation, validation and implementation data.
Generate ‘selection’ and ‘implementation’ criteria:
Criteria can be individually prioritized dependent on the local requirements of each medical
institution (also Tables 2 & 4).
The size and composition of medical personnel employed at different medical institutions e.g.
the ratio of doctors, nurses, diagnosticians, technicians etc, may influence the prioritization of
the institutional selection criteria.
How will ID-POCT interact with current laboratory management information systems (LIMS)?
Patient safety and data security?
Establish an internal pilot study for comparison with current ‘gold standard’ test.
ID-POCT management and quality control and quality assurance procedures:
A standardized and regular quality control/assurance scheme should be implemented
within the institution to monitor and ensure the maintenance of, or improvements in,
current standards of patient care (also Tables 3 & 4).
Training of relevant personnel in the use of ID-POCT is essential.
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adaptation of the guidelines may be necessary in 
order to meet with local or national requirements.
An ‘overview of the ID-POCT pre-implemen-
tation process’ per se is shown in Figure 1, includ-
ing several ‘alternative routes’ that may be taken 
dependent on individual circumstances within 
different medical institutions. For the implemen-
tation of ID-POCT on a small scale i.e. institu-
tions with only one or two medical departments, 
creating and circulating an ID-POCT question-
naire may not be necessary as the opinions of 
end-users can be simply obtained via face-to-face 
discussions. However, this particular alternative 
route is not recommended for larger medical 
institutions, or where there is a debate regard-
ing which particular ID-POCT device is most 
suitable for implementation. Similarly, it is not 
absolutely necessary to develop contacts with 
ID-POCT manufacturers for the small-scale use 
of ID-POCT. However, ID-POCT manufactur-
ers can be a good source of rapid information 
regarding new developments for their particu-
lar ID-POCT device, and if large quantities of 
consumables will be required for a particular 
ID-POCT, then it may be possible to negoti-
ate financial discounts, especially if there is the 
possibility of competition between two or more 
ID-POCT companies for your business.
tables 1–3 and Box 1 provide more detail to 
Figure 1 and group the guidelines into general 
themes relating to: suggested ‘dissemination pipe-
lines’ (table 1) – essentially, knowledge gathering 
and knowledge dissemination guidelines in order 
to understand and react to the needs and percep-
tions of ID-POCT stakeholders, thereby providing 
a broad base on which to build ID-POCT imple-
mentation discussions; potential ‘selection criteria’ 
(Box 1) – considerations which may be relevant to 
ID-POCT stakeholders in different medical insti-
tutions; ‘pro-active’ interactions (table 2) – gen-
erating institution-specific ID-POCT purchase 
and implementation guidelines; and ID-POCT-
specific pre-implementation issues (table 3) – there 
are several ID-POCT preimplementation issues 
which are particularly important for certain types 
of ID-POCT devices and situations.
Consultation and/or adoption of these guide-
lines will establish a firm foundation for the 
table 1. suggested ‘dissemination pipelines’ for distributing institutional infectious disease point-of-care test information (both 
internally and externally).
Pipeline comments
Institution-wide ‘intranet site’ and or ‘service portal’  ● What potentially appropriate ID-POCT are available within and 
outside the medical center?
 ● Keep up-to-date with new advances in the market 
Create a dedicated institutional ID-POCT website where colleagues 
can obtain ID-POCT information when they need it (a simple 
website could be created with links to external sources of 
information [10])
 ● Include these guidelines, implementation costs, quality control 
issues, etc
 ● Create an internal ID-POCT discussion forum
Individual lectures and face-to-face meetings Generate new ID-POCT learning materials including e-learning 
modules and self-study materials
Online Communicate your medical institutions experiences with ID-POCT via 
Youtube, Facebook or Twitter
Conferences and scientific publications  ● Present your implementation experiences at scientific conferences
 ● Publish the results of your institutions ID-POCT questionnaire (if 
applicable)
 ● Publish your own findings regarding quality of ID-POCT devices, for 
example, sensitivity, specificity etc
Determine consequences of ID-POCT testing on current and future 
research and education activities (applicable to medical institutions 
with academic responsibilities)
Effect of ID-POCT on the maintenance of up-to-date and state-of-the-
art teaching and training programs in the rapidly changing field of 
medical diagnostics
Prepare standard communication texts – leaflets etc. – informing 
patients of the advantages and disadvantages of using (a specific) 
ID-POCT
Patients should be considered as stakeholders and therefore 
informed over the reasons for implementing ID-POCT (particularly in 
comparison with current ‘gold standard’ laboratory-based techniques)
ID-POCT: Infectious disease point-of-care test.
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successful implementation of ID-POCT within 
many different types of medical institutions. 
Further, ID-POCT assay manufacturers will 
receive the opportunity to pro-actively inform 
and interact at all stages within the ID-POCT 
implementation process. However, it should be 
noted that such interactions should be mutu-
ally beneficial and ideally based on solid sci-
entific evidence or previous implementations 
of ID-POCT assays into the medical environ-
ment, rather than simply being a ‘lobbying’ 
or ‘sales’ exercise by individual ID-POCT 
assay manufacturers/developers to individual 
medical institutions. The large scale success-
ful implementation of ID-POCT in medical 
institutions could ultimately be beneficial for 
all ID-POCT stakeholders, including clini-
cians, diagnosticians, laboratory managers, 
healthcare providers and (most importantly) 
patients themselves.
Finally, it should be noted that the main 
emphasis of these guidelines has been directed 
toward the implementation of ID-POCT 
within medical institutions per se, rather than 
the development of guidelines for the use 
of (disposable) ID-POCT in: ‘low experi-
ence’ environments, for example, patients at 
home; ‘extreme’ environments, for example, 
battlefield situations, astronauts in space etc. 
or ‘limited resource’ environments, for exam-
ple, in developing countries during infec-
tious disease epidemics (Ebola, Zika viruses, 
Enterohemorrhagic Escherichia coli food-borne 
disease outbreaks etc.) where medical person-
nel may be at special risk of (nosocomial) infec-
tion or staff shortages may occur. However, 
this does not mean that the above guidelines 
are invalid for these situations, rather that 
individual guidelines may have to be adapted, 
ignored or some guidelines given more ‘weight’ 
than other guidelines in order to best serve 
the requirements of the individual situation, 
for example, user education, urgency of the 
situation; explosive increase in ID-POCT 
throughput requirements, ID-POCT compo-
nent stability, ID-POCT costs etc. Ultimately, 
it is the choice of the (end) user who will deter-
mine which guidelines are useful for their own 
p articular situation.
conclusion
POCT has the potential to transform current 
healthcare practices. However, (pre-)imple-
mentation issues may be limiting the introduc-
tion and successful use of POCT within many 
medical environments and institutions. This 
table 2. ‘Pro-active’ interactions available to medical institutions and infectious disease point-of-care test manufacturers to help 
them with infectious disease point-of-care test implementation.
interaction iD-POct manufacturer/developer working together 
with medical institutions
comments
Make and maintain contacts with institutional ID-POCT working 
groups
Making contacts with individual end-users, for example, heads of 
departments, may not be sufficient in helping implement ID-POCT 
test assays in medical institutions
Understand the key institutional workflows and current gold 
standard testing criteria
Use the ID-POCT working group and individual end-users as a source 
of advice regarding individual institutional workflows
Identify where a particular ID-POCT test assay would bring 
advantages over existing institutional workflows and report this to 
the relevant ID-POCT working group
Possible advantages include: increased specificity, increased 
sensitivity, decreased costs, decreased time to result, increased 
throughput, ease of use, etc
Keep the ID-POCT working group up to date on new developments 
within the fields of individual ID-POCT test assays
How is/has the ID-POCT test assay being/been developed/updated to 
meet the specific requirements of individual medical institutions?
Provide details of relevant scientific publications to institutional ID-
POCT working groups and end-users
What scientific evidence is available regarding the test characteristics 
of the ID-POCT test assay?
Provide details of relevant medical institutions where the ID-POCT 
has already been successfully established
Be aware that individual workflows may vary between different 
medical institutions, so ‘one size may not fit all’
Identify institutional ID-POCT test assay selection criteria at an early 
stage and develop the ID-POCT test assay to take into account these 
institutional needs
Try to develop ID-POCT test assays which meet as many selection 
criteria as possible
Identify institutional ID-POCT test assay selection criteria at an early 
stage and develop a business model based on these criteria
Try to develop a business model which can successfully compete with 
current (and future) financial criteria managed by medical institutions
Keep up-to-date with the results of ID-POCT funding awards and 
opportunities
Current examples include the ‘Longitude Prize’ [11] and the ‘Better Use 
of Antibiotics’ Prize [12]
ID-POCT: Infectious disease point-of-care test.
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Box 1. List of potential ‘selection criteria’ for consideration prior to infectious disease point-of-care test implementation.
Technology
 ●  The extent to which the technology:
 ● Is valuable and affordable
 ● Has been evaluated – including in the scientific literature – with respect to specimen collection, specificity, sensitivity, reproducibility, 
cost per test etc
 ● Fits within the existing IT infrastructure (e.g., security, bandwidth)
 ● Requires certification (appropriate for regional, national or international regulations where the ID-POCT will be performed)
 ● Is applicable to the work environment, for example, hospital general wards, emergency rooms, family doctors’ offices
Implementation
 ●  Is the test approved for use by (inter)national regulatory authorities?
 ●  The simplicity of complying with existing laws and regulations
 ●  The extent to which the new service can be incorporated into existing workflows
 ●  Are the appropriate resources available (including extra laboratory capacity)?
 ●  The degree to which the risks associated with implementation can be controlled
 ●  The speed at which the new ID-POCT test service can be launched
 ●  Cultural barriers – perceived lack of confidentiality and individual/societal stigma associated with the result, for example, HIV rapid tests
Use and alternatives
 ●  The degree of acceptance by medical institution care providers and customers/clients for this kind of service
 ●  The number of clients who would want/can/should use the new ID-POCT test service
 ●  The growth expectation for the ID-POCT test new service
 ●  Are there alternatives to the new ID-POCT test service available?
Operation
 ●  Interconnectivity of ID-POCT with existing labratory information management systems for your institution.
 ●  Simplicity in learning to use the new ID-POCT technology
 ●  Availability of training courses for doctors, nurses, technicians etc. and planning for regular (re-)accreditation/(re-)certification
 ●  Are the consumable materials required for the new ID-POCT test service available?
 ●  The ease by which ID-POCT problems can be solved by medical institution personnel, for example, self-repairs
Costs
 ●  The extent of funding for the development of the ID-POCT test service in question
 ●  Cost of replacing existing laboratory equipment (if applicable)
 ●  Cost of training and maintaining ID-POCT user expertise
 ●  Need for additional, or frequency, of quality control/quality assurance programs
 ●  Is reimbursement available for ID-POCT use (insurance companies or healthcare providers)?
 ●  The price of ID-POCT fits with economic and financial restrictions, for example, low- and middle-income countries?
 ●  The time required before the investment is recouped
 ●  The financial risks can be controlled
Strategy
 ●  The extent by which the new ID-POCT test service:
 ● Encourages health-related participation with society
 ● Enhances the independence of patients
 ● Supports efficiency in the care process
 ● Contributes to a positive image of the medical environment
ID-POCT: Infectious disease point-of-care test.
is especially true for ID-POCT. Therefore, 
in this publication, the authors provide pre-
implementation guidelines for consideration 
by ID-POCT stakeholders, including health-
care workers, laboratory managers, financiers 
and POCT developers, when deciding on the 
possible implementation of ID-POCT within 
medical institutions.
Future perspective
The implementation of ID-POCT offers 
much potential, but currently lags behind the 
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table 3. iD-POct specific Pre-implementation issues.
specific iD-POct issue comments
ID-POCT generally detect multiple 
targets during the testing of a single 
specimen
 
 
 ● Should the clinician ignore the results from targets that have not been requested?
 ● What are the legal and moral issues associated with ignoring test results obtained (but not 
requested) by the clinician?
 ● Are healthcare providers willing to pay for the costs of these extra tests (compared to the use of a 
single target-specific ID-POCT), even if these are not requested by the clinician?
Quality control and quality assurance 
of ID-POCT multiple target detection 
devices is more complex than single 
target POCT
 ● How often should each target be QC/QA? If an ID-POCT can detect 20 targets simultaneously, 
should all 20 targets receive QC/QA at the same time? If a target only receives QC/QA once every 
3 months, instead of for example once every month, then many more patients may have to be 
informed that their test results were incorrect if that 3 monthly test fails. This could lead to higher 
morbidity and mortality compared to a ID-POCT which receives QC/QA every week or month
 ● What are the extra costs involved in the quality control/quality assurance of multi-target ID-POCT?
 ● Is there a reliable supplier of reference material for each of the targets in a multi-target ID-POCT?
 ● Will healthcare providers be willing to pay for additional QC/QA testing for rare, or unused targets?
 ● Sample collection and storage issues should be discussed, agreed and implemented in order to 
provide a biobank of duplicate patient samples in case quality control procedures indicate that the 
ID-POCT has failed
Potential use of emergency 
legislation in times of biological 
crises
Be aware of emergency legal issues, for example, the US FDA EUA. “Under section 564 of the Federal 
Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical 
products or unapproved uses of approved medical products to be used in an emergency to diagnose, 
treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, 
radiological and nuclear defence threat agents, when there are no adequate, approved, and available 
alternatives” [13,14]
Provision of personal protective 
equipment, high risk testing, and 
isolation units
The explosive spread of highly infectious agents e.g. Zika, Ebola, MERS-CoV, may require the rapid 
implementation of ID-POCT. Suitable protocols, training and equipment need to be available in order 
to ensure the success of the rapid implementation of ID-POCT, especially if these tests do not form 
part of the ‘normal’ diagnostic packet of medical institutions
Access to reference material Currently, specimens sent to microbiology laboratories for the detection of infectious disease 
pathogens provide an extremely useful resource for epidemiological studies, as well as being a source 
of novel microbial pathogens. If ID-POCT becomes widely used in hospital wards, at family doctor 
practices, or even at home, what will the effect be on the successful tracking and surveillance of 
microbial pathogens? Think for example about the yearly production of an effective influenza vaccine, 
or the efficient monitoring of carbapenem antibiotic resistance in Europe
Universal primers In order to provide broad coverage for the detection of a specific microbial pathogen, ID-POCT tend 
to use primers directed against universal sequences that are present within all known members of a 
particular microbial species. This means that there will be much less information available regarding 
the epidemiology of specific microbial strains compared with, for example a ‘catch-all’ technique 
such as bacterial culture (where bacteria can be cultured and their specific epidemiological profiles 
determined by further processing e.g. gene sequencing)
Next generation sequencing ID-
POCT
 
 ● One exception to the ‘access to reference material’ and ‘universal primers’ comments mentioned 
above, is the use of next-generation sequencing-based ID-POCT, which could provide specific 
epidemiological information on the target pathogen detected. However, there may be potentially 
multiple pathogens present within a clinical sample and the experience of clinicians may be required 
in order to determine which potential pathogen is associated with the current disease state
 ● Next-generation sequencing ID-POCT may require intensive bioinformatics and software support, 
which means that this kind of test may not be (currently) suitable for applications outside of 
secondary or tertiary care medical institutions. Additionally, algorithms will need to be developed 
which simulate the ‘experience of clinicians’ when making decisions regarding the relative 
contribution of a potential pathogen to the current disease state
EUA: Emergency use authorization; ID-POCT: Infectious disease point-of-care test; QA: Quality assured; QC: Quality control.
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POCT advances associated with other clinical 
disciplines. The successful implementation of 
ID-POCT in the future will be characterized 
by: a shift in emphasis from ‘technologically 
based’ to ‘clinically based’ ID-POCT solutions; 
a general acceptance of ID-POCT by the medi-
cal profession (most likely led by an increase 
in awareness of the advantages of ID-POCT 
at family doctor practices, in emergency rooms 
and in the home environment); the develop-
ment of scientific/manufacturing pipelines; 
and the adoption of ID-POCT for monitoring 
and control of new diseases and (exotic) disease 
outbreaks. However, one of the main remaining 
obstacles to the implementation of ID-POCT 
will still be its financial reimbursement.
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executive summary
 ●  The implementation of dedicated infectious disease point-of-care test (ID-POCT) devices into medical institutions 
tends to lag behind that of POCT devices used in many other medical disciplines.
 ●  There exist crucial preimplementation differences between POCT and ID-POCT before their implementation into 
medical institutions.
 ●  The authors present a simple, but ‘holistic’ set of ID-POCT guidelines that can be used by ID-POCT stakeholders to 
guide their preimplementation ID-POCT decision-making processes.
 ●  ‘Dissemination pipelines’ provides knowledge gathering and dissemination guidelines in order to understand and 
react to the needs and perceptions of ID-POCT.
 ●  Potential ‘selection criteria’ considers the selection criteria which may be relevant to ID-POCT stakeholders in different 
medical institutions.
 ●  ‘Pro-active’ interactions describes how medical institutions and ID-POCT manufacturers can positively interact in order 
to facilitate successful ID-POCT implementation.
 ●  ID-POCT specific pre-implementation issues indicate those pre-implementation issues that are particularly important 
for certain types of ID-POCT and situations.
 ●  Consultation and/or adoption of these guidelines will establish a firm foundation for the successful implementation of 
ID-POCT within many different types of medical institutions.
 ●  These guidelines may need to be adapted in special circumstances involving: ‘low experience’, ‘extreme’ and ‘limited 
resource’ environments.
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